Hematological Malignancies
Showing NaN - NaN of 9
Hematological Malignancies Trial in United Kingdom, United States (Magrolimab, Azacitidine)
Active, not recruiting
- Hematological Malignancies
- Magrolimab
- Azacitidine
-
Duarte, California
- +26 more
Dec 7, 2022
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies Trial in Worldwide (Durvalumab / Tremelimumab Combination
Active, not recruiting
- Pediatric Cancer
- +2 more
- Durvalumab / Tremelimumab Combination Therapy
-
Baltimore, Maryland
- +18 more
Nov 3, 2022
MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular
Recruiting
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- +8 more
-
Boston, Massachusetts
- +6 more
Apr 14, 2022
Hematological Malignancies Trial in Boston, Durham (Pasireotide)
Completed
- Hematological Malignancies
-
Boston, Massachusetts
- +1 more
Oct 19, 2021
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) Trial in Worldwide (NiCord®
Active, not recruiting
- Hematological Malignancies
- +6 more
- NiCord® (omidubicel)
- Cord Blood Unit
-
Los Angeles, California
- +51 more
Jan 7, 2021
Hematological Malignancies Trial in Boston (Rituximab, 375 mg/m2 RRituximab)
Completed
- Hematological Malignancies
- Rituximab
- 375 mg/m2 RRituximab
-
Boston, MassachusettsDana-Farber Cancer Institute
Feb 3, 2014
